Compounded Hyperpigmentation Preparations

Unlabeled white cream jar and pump bottle beside a folded towel

Topical preparations combining agents that act at different points in melanin production and transfer.

When a prescriber may consider it

Melasma, post-inflammatory hyperpigmentation and post-procedural pigmentary change, where a commercial product has been insufficient for the patient or the patient cannot tolerate a component.

FDA-approved landscape first

Tri-Luma (fluocinolone, hydroquinone and tretinoin) is the FDA-approved combination product for melasma. Prescription single-agent hydroquinone is also widely dispensed. ALWAYS Rx dispenses both. Where an approved product meets the clinical need, it is generally the appropriate first consideration. Status: FDA-Approved Product (Tri-Luma).

Active ingredients and role

Hydroquinone (tyrosinase inhibition), kojic acid (tyrosinase inhibition), tretinoin (increased epidermal turnover), tranexamic acid (plasmin pathway), ascorbic acid (antioxidant), niacinamide (melanosome transfer), and hydrocortisone, fluocinolone and triamcinolone (anti-inflammatory). Oral tranexamic acid capsules are also compounded for hyperpigmentation; this is an off-label use.

Dosage forms

Cream, gel, solution, capsule.

Safety

Tretinoin is contraindicated in pregnancy. Prolonged hydroquinone use requires prescriber oversight. Topical corticosteroids carry a risk of skin atrophy with extended use. Oral tranexamic acid carries a risk of blood clots; the risk increases with higher doses, longer treatment and some other medications, and prescriber screening is required before and during treatment. Sun protection materially affects outcome in pigmentary conditions.

Status: Compounded Option; oral tranexamic acid is Off-Label Clinical Use.

Patients: Transfer a Prescription

Compounded preparations are not FDA approved. FDA does not review them for safety, effectiveness or quality before they are dispensed, and they are not equivalent to commercially available approved products. California requires a patient-specific prescription for a compounded preparation, and a pharmacy may not compound what is essentially a copy of a commercially available product unless the pharmacist documents a clinically significant difference for the individual patient or the product is in shortage. This page is general information, not medical advice.

References

Clinical review: Dor Keyvani, PharmD, Pharmacist-in-Charge, California pharmacist license RPH 75634. Clinically reviewed Oct. 20, 2026. Updated Nov. 10, 2026. See our Editorial Policy and Quality and Safety pages.